BAJAJ BROKING

Notification close image
No new Notification messages
card image
Vikram Solar IPO is Open!
Apply for the Vikram Solar IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Marksans Pharma Q1 Results FY25-26: Revenue Up 5% YoY; PAT Down 34.7%

Marksans Pharma Q1 Results FY25-26: Revenue Up 5% YoY; PAT Down 34.7%

Key Highlights 

  • Revenue from operations: ₹620 crore, up 5% YoY

  • Gross profit: ₹358.2 crore, up 8.9% YoY; gross margin expanded 209 bps to 57.8%

  • EBITDA: ₹100.1 crore, down 22% YoY; margin at 16.1%

  • PAT: ₹58.2 crore, down 34.7% YoY

  • EPS: ₹1.3, vs ₹2.0 in Q1 FY25

  • Cash balance stood at ₹711 crore as of 30 June 2025

MARKSANS PHARMA LIMITED

Trade

184.255.66 (3.16 %)

Updated - 18 August 2025
184.90day high
DAY HIGH
180.00day low
DAY LOW
1532036
VOLUME (BSE)

Quarterly – Marksans Pharma Q1 Results FY25-26

Particulars

Q1 FY26

Q4 FY25

Q1 FY25

YoY %

QoQ %

Revenue from Operations

620.0

708.5

590.6

5.0%

-12.5%

Gross Profit

358.2

383.2

328.8

8.9%

-6.5%

Gross Margin (%)

57.8%

54.1%

55.7%

+209 bps

+368 bps

EBITDA

100.1

126.9

128.4

-22.0%

-21.1%

EBITDA Margin (%)

16.1%

17.9%

21.7%

-560 bps

-177 bps

PAT

58.2

90.7

89.1

-34.7%

-35.8%

Net Margin (%)

9.3%

12.5%

14.7%

-541 bps

-323 bps

EPS (₹)

1.3

2.0

2.0

-34.3%

-35.6%

Net Cash from Operations

48.7

Capex

37.8

Cash Balance

711

R&D Spend

12.1

All figures in ₹ crore unless otherwise stated

Segment Highlights

Segment

Q1 FY26 (₹ Cr)

Q1 FY25 (₹ Cr)

YoY %

Revenue Mix

US & North America

327.6

250.9

30.6%

52.8%

UK & Europe

203.8

251.5

-19.0%

32.9%

Australia & NZ

57.0

65.6

-13.1%

9.2%

Rest of World (ROW)

31.6

22.7

39.4%

5.1%

Total

620.0

590.6

5.0%

100%

Sector Expectations for Marksans Pharma Q1 Results FY25-26

Pharma sector peers generally saw mid-to-high single-digit revenue growth, supported by easing input costs and selective product launches in export markets. Marksans’ 5% revenue growth aligns with this trend, though the 560 bps drop in EBITDA margin reflects short-term operational and cost pressures that some peers avoided.

Management Commentary

Mark Saldanha, Managing Director of the Company, said, “While Q1FY26 was a seasonally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in the US markets and the easing of raw material costs. While EBITDA and net profit margins were impacted by ramp-up costs, a one-time ECL provision for the emerging market division, and forex adjustments, these are transient and do not affect the fundamental momentum of our business. We are already seeing encouraging early signs of demand recovery in key markets such as the U.S., U.K., and Australia. With the Goa facility integration nearing completion, we are now sharply focused on scaling capacity, enhancing operational efficiency, and unlocking synergies. Our execution discipline, combined with a robust pipeline and expanding market presence, positions us well to deliver sustainable, long-term value. We remain committed to driving growth, improving returns, and creating enduring value for our stakeholders in FY26 and beyond.” 

Source: Q1 FY25-26 Quarterly Results uploaded on 12th August 2025, on BSE.

For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|